Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6
-
Published:2023-10
Issue:4
Volume:84
Page:e94-e95
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Ardolino Luke C.,
Dear Rachel,
Armstrong Andrew J.,
Gillessen Silke,
Joshua Anthony M.ORCID
Reference5 articles.
1. Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: limitations of the VISION trial;Olivier;Eur Urol,2023
2. Morris MJ, Sartor O, de Bono JS, Fizazi K, Tagawa ST. Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: limitations of the VISION trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.028.
3. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects;World Medical Association;JAMA,2013
4. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021
5. Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future;Ardolino;Ann Oncol,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献